Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Summary

A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK). The purpose of this first-time-in-human study is to evaluate the safety and immunogenicity profile of a low and a full dose of the investigational vaccine, formulated with or without adjuvant, administered in 2 doses, 24 weeks apart, in healthy adults 18 to 50 years of age in Europe.

Timeline

Start

2022-11-28

Primary completion

2023-12-06

Completion

2024-04-02

Publications

• De Coster I, AbdelGhany M, Sarakinou E, Fineschi C, Marchetti E, La Gaetana R, Nigro S, Carducci M, Massai L, Conti V, Rossi O, Luna Cilio G, Serry-Bangura A, Tessitore P, Van Damme P, Withanage K, Micoli F, Berlanda Scorza F, Rondini S, Nakakana UN, Kumar Arora A. Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial. Lancet Infect Dis. 2026 Jun;26(6):638-650. doi: 10.1016/S1473-3099(25)00730-3. Epub 2026 Jan 23.

Drugs

Indications